Alterations of immune cell subsets in relapsed, thymoma-associated minimal change disease: A case report

Gharwan,Helen; Tomita,Yusuke; Lee,Min‑Jung; Thomas,Anish; Berman,Arlene; Giaccone,Giuseppe; Trepel,Jane; Rajan,Arun

doi:10.3892/ol.2015.3325

August-2015 Volume 10 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August-2015 Volume 10 Issue 2

Full Size Image

Case Report

Alterations of immune cell subsets in relapsed, thymoma-associated minimal change disease: A case report

Authors:
- Helen Gharwan
- Yusuke Tomita
- Min‑Jung Lee
- Anish Thomas
- Arlene Berman
- Giuseppe Giaccone
- Jane Trepel
- Arun Rajan
View Affiliations / Copyright

Affiliations: Thoracic and Gastrointestinal Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892‑1906, USA, Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892‑1906, USA, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA
Pages: 1155-1158
|
Published online on: June 5, 2015

https://doi.org/10.3892/ol.2015.3325
Expand metrics +

Abstract

The most frequently described glomerulopathy in patients with thymoma is minimal change disease (MCD). The present study reports the case of a 63‑year‑old female with recurrent thymoma and poorly‑controlled paraneoplastic MCD, who was enrolled on a phase I/II clinical trial (no. NCT01100944) and treated with the histone deacetylase inhibitor, belinostat, in combination with cisplatin, doxorubicin and cyclophosphamide. Treatment resulted in a complete radiological response, a dramatic reduction in proteinuria and changes in immune cell subset composition, consisting of a reduction in the number of T helper (Th)1, Th2, Th17 and regulatory T cells. Changes in T‑cell polarization were also observed with an increase in the Th1/Th2 ratio. To the best of our knowledge, the current study is the first to provide a detailed description of changes in immune cell subset composition in thymoma‑associated MCD. Early administration of effective antitumor therapy should be considered in these cases, particularly when proteinuria is poorly controlled despite the use of steroids and other immunosuppressive therapies.

View Figures

View References

1	Nachman PH, Jennette JC and Falk R: Primary glomerular diseaseThe Kidney. Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu ASL and Brenner BM: Elsevier; Philadelphia, PA: pp. 1100–1191. 2012
2	Hogan J and Radhakrishnan J: The treatment of minimal change disease in adults. J Am Soc Nephrol. 24:702–711. 2013. View Article : Google Scholar : PubMed/NCBI
3	Chugh SS, Clement LC and Macé C: New insights into human minimal change disease: Lessons from animal models. Am J Kidney Dis. 59:284–292. 2012. View Article : Google Scholar : PubMed/NCBI
4	Lien YH and Lai LW: Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis. Nat Rev Nephrol. 7:85–95. 2011. View Article : Google Scholar : PubMed/NCBI
5	Koga K, Matsuno Y, Noguchi M, Mukai K, Asamura H, Goya T and Shimosato Y: A review of 79 thymomas: Modification of the staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int. 44:359–367. 1994. View Article : Google Scholar : PubMed/NCBI
6	Travis WD, Brambilla E, Müller-Hermelink HK and Harris CC: Tumors of the thymusWorld Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. IARC Press; Lyon, France: pp. 146–248. 2004
7	Thomas A, Rajan A, Szabo E, Tomita Y, et al: A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: A clinical and translational study. Clin Cancer Res. 20:5392–5402. 2014. View Article : Google Scholar : PubMed/NCBI
8	Liu LL, Qin Y, Cai JF, Wang HY, Tao JL, Li H, Chen LM, Li MX, Li XM and Li XW: Th17/Treg imbalance in adult patients with minimal change nephrotic syndrome. Clin Immunol. 139:314–320. 2011. View Article : Google Scholar : PubMed/NCBI
9	Nishikawa H and Sakaguchi S: Regulatory T cells in cancer immunotherapy. Curr Opin Immunol. 27:1–7. 2014. View Article : Google Scholar : PubMed/NCBI
10	Le Berre L, Bruneau S, Naulet J, Renaudin K, Buzelin F, Usal C, Smit H, Condamine T, Soulillou JP and Dantal J: Induction of T regulatory cells attenuates idiopathic nephrotic syndrome. J Am Soc Nephrol. 20:57–67. 2009. View Article : Google Scholar : PubMed/NCBI
11	Lien YH and Lai LW: Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis. Nat Rev Nephrol. 7:85–95. 2011. View Article : Google Scholar : PubMed/NCBI
12	Le Berre L, Hervé C, Buzelin F, Usal C, Soulillou JP and Dantal J: Renal macrophage activation and Th2 polarization precedes the development of nephrotic syndrome in Buffalo/Mna rats. Kidney Int. 68:2079–2090. 2005. View Article : Google Scholar : PubMed/NCBI
13	Rajan A, Kotlyar D and Giaccone G: Acute autoimmune hepatitis, myositis, and myasthenic crisis in a patient with thymoma. J Thorac Oncol. 8:e87–e88. 2013. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Alterations of immune cell subsets in relapsed, thymoma-associated minimal change disease: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles